Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

Document Type

Journal Article

Publication Date

7-1-2019

Journal

The lancet oncology

Volume

20

Issue

7

Inclusive Pages

1011-1022

DOI

10.1016/S1470-2045(19)30277-3

Peer Reviewed

1

Share

COinS